{
  "data": [
    {
      "id": "doc-redecan-2025",
      "source_id": "redecan-2025",
      "title": "Estimación de la incidencia del cáncer en España, 2025",
      "url": "https://redecan.org/storage/documentation/442e1d1a-4040-4674-81cf-5e6a67af6458.pdf",
      "r2_key": "original/redecan-incidencia-2025.pdf",
      "sha256": "70a56cff810b66d18857a97c78095aced943d686bbdbaf860d06d78ba726c5fe",
      "published_at": "2025",
      "consulted_at": "2026-11-06",
      "mime_type": "application/pdf",
      "retention_note": "Original público conservado"
    },
    {
      "id": "doc-farmacia-2024",
      "source_id": "sanidad-farmacia-2024",
      "title": "Prestación Farmacéutica en el SNS 2024",
      "url": "https://www.sanidad.gob.es/estadEstudios/estadisticas/sisInfSanSNS/tablasEstadisticas/InfAnual2024/Monografico_PrestacionFarmaceutica_2024.pdf",
      "r2_key": "original/sns-farmacia-2024.pdf",
      "sha256": "72aa469c369a2e045c2701a3be83006302f9b8ada5f64dac3e2bae408fed98ab",
      "published_at": "2026",
      "consulted_at": "2026-11-06",
      "mime_type": "application/pdf",
      "retention_note": "Original público conservado"
    },
    {
      "id": "doc-cipm-250",
      "source_id": "cipm-250",
      "title": "Acuerdos CIPM 250, 26 septiembre 2024",
      "url": "https://www.sanidad.gob.es/areas/farmacia/precios/comisionInteministerial/acuerdosNotasInformativas/docs/ACUERDOS_CIPM_250.pdf",
      "r2_key": "original/cipm-250.pdf",
      "sha256": "8b819fa93e2c4c8557a808ef25800925836a0d196d41e1e0a7fa55f69641f355",
      "published_at": "2024-09-26",
      "consulted_at": "2026-11-06",
      "mime_type": "application/pdf",
      "retention_note": "Original público conservado"
    },
    {
      "id": "doc-ipt-44",
      "source_id": "ipt-44-avelumab",
      "title": "IPT 44/2022 Avelumab",
      "url": "https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/2022/IPT_44-2022-Bavencio.pdf",
      "r2_key": "original/ipt-44-avelumab.pdf",
      "sha256": "3025f272d083bf93c30fdceb3f5df63abf208ccc57a7b7ff3aec2eb2399419b8",
      "published_at": "2022-06-01",
      "consulted_at": "2026-11-06",
      "mime_type": "application/pdf",
      "retention_note": "Original"
    },
    {
      "id": "doc-ipt-203",
      "source_id": "ipt-203-enfortumab",
      "title": "IPT 203/2023 Enfortumab",
      "url": "https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/2023/IPT-203-Enfortumab-vedotina-Padcev.pdf",
      "r2_key": "original/ipt-203-enfortumab.pdf",
      "sha256": "c66267c417ef1ab4d27f7963c80bbfddea27d10cfddba86cef0ff6bff1a49c44",
      "published_at": "2023-11-21",
      "consulted_at": "2026-11-06",
      "mime_type": "application/pdf",
      "retention_note": "Original"
    },
    {
      "id": "doc-cipm-258",
      "source_id": "cipm-258",
      "title": "CIPM 258 Balversa",
      "url": "https://www.sanidad.gob.es/areas/farmacia/precios/comisionInteministerial/acuerdosNotasInformativas/docs/ACUERDOS_CIPM_258.pdf",
      "r2_key": "original/cipm-258.pdf",
      "sha256": "72ef4cda9d75070f25a6a7096dedaf868017c594e422e861f0440fcccc17a7d8",
      "published_at": "2025-04-24",
      "consulted_at": "2026-11-06",
      "mime_type": "application/pdf",
      "retention_note": "Original"
    },
    {
      "id": "doc-sanidad-hosp-2025",
      "source_id": "sanidad-hosp-2025",
      "title": "Consumo hospitalario diciembre, acumulado anual 2025",
      "url": "https://www.sanidad.gob.es/areas/farmacia/consumoMedicamentos/hospitalario/2025/diciembre.htm",
      "r2_key": null,
      "sha256": null,
      "published_at": "2025-12",
      "consulted_at": "2026-11-06",
      "mime_type": "text/html",
      "retention_note": "tablas acumulado ene–dic; URL exacta y fecha"
    },
    {
      "id": "doc-avebladder",
      "source_id": "avebladder-2025",
      "title": "Avelumab maintenance in advanced urothelial carcinoma: real-world data from Northern Spain (AVEBLADDER study)",
      "url": "https://repositorio.uneatlantico.es/17813/1/s12094-025-03950-w.pdf",
      "r2_key": "evidence/avebladder-2025.pdf",
      "sha256": "43652fbf3d975bad626f62b94a5975a437648c4ab6240224bb24aeb9ae813a3a",
      "published_at": "2025",
      "consulted_at": "2026-11-06",
      "mime_type": "application/pdf",
      "retention_note": "p2 resultados primera línea; p3 avelumab; tabla 1; periodo 2021–2023"
    },
    {
      "id": "doc-catsalut-rpt",
      "source_id": "catsalut-rpt",
      "title": "Avelumab (C. urotelial manteniment 1L) / RPT MHDA",
      "url": "https://catsalut.gencat.cat/ca/detalls/articles/avelumab-c-urotelial-manteniment-1l",
      "r2_key": null,
      "sha256": null,
      "published_at": "2022-09-20",
      "consulted_at": "2026-11-06",
      "mime_type": "text/html",
      "retention_note": "existencia registro y variables; sin agregados"
    },
    {
      "id": "doc-valtermed",
      "source_id": "valtermed-coverage",
      "title": "VALTERMED listado protocolos farmacoclínicos",
      "url": "https://www.sanidad.gob.es/areas/farmacia/infoMedicamentos/valtermed/",
      "r2_key": null,
      "sha256": null,
      "published_at": null,
      "consulted_at": "2026-11-06",
      "mime_type": "text/html",
      "retention_note": "listado consultado; avelumab no figura"
    },
    {
      "id": "doc-bifimed-719163",
      "source_id": "bifimed-719163",
      "title": "BIFIMED avelumab CN 719163",
      "url": "https://www.sanidad.gob.es/profesionales/medicamentos.do?cn=719163&metodo=verDetalle",
      "r2_key": null,
      "sha256": null,
      "published_at": "2026-11",
      "consulted_at": "2026-11-06",
      "mime_type": "text/html",
      "retention_note": "Seguimed, aprobación financiación histórica y actual"
    },
    {
      "id": "doc-blarwe",
      "source_id": "blarwe-2025",
      "title": "BLARWE — cohorte cáncer de vejiga",
      "url": "https://www.eu-openscience.europeanurology.com/article/S2666-1683(25)01713-6/pdf",
      "r2_key": null,
      "sha256": null,
      "published_at": "2025",
      "consulted_at": "2026-11-06",
      "mime_type": "application/pdf",
      "retention_note": "enlace directo artículo, proporciones usadas; cohorte 2018"
    },
    {
      "id": "doc-puente",
      "source_id": "puente-2025",
      "title": "Puente et al. — líneas tratamiento urotelial avanzado",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39365365/",
      "r2_key": null,
      "sha256": null,
      "published_at": "2025",
      "consulted_at": "2026-11-06",
      "mime_type": "text/html",
      "retention_note": "829 pacientes; periodo 2015–2020"
    },
    {
      "id": "doc-proc-awarded",
      "source_id": "ted-347920-2024",
      "title": "Tres adjudicaciones seleccionadas: enlaces originales en registro y fuentes",
      "url": "https://ted.europa.eu/en/notice/-/detail/347920-2024",
      "r2_key": null,
      "sha256": null,
      "published_at": "2024",
      "consulted_at": "2026-11-06",
      "mime_type": "text/html",
      "retention_note": "TED 347920-2024 + TED 333880-2024 + La Paz PNSP 29/2024; total 4.370.602 EUR sin IVA, no gasto ejecutado"
    },
    {
      "id": "doc-proc-executed",
      "source_id": "ted-333880-2024",
      "title": "Ejecución contractual: registro de búsqueda negativa",
      "url": "https://ted.europa.eu/en/notice/-/detail/333880-2024",
      "r2_key": null,
      "sha256": null,
      "published_at": null,
      "consulted_at": "2026-11-06",
      "mime_type": "text/html",
      "retention_note": "No localizada ejecución atribuible en fuentes consultadas; adjudicación no prueba consumo"
    },
    {
      "id": "doc-seom-avances-vejiga-2025",
      "source_id": "seom-avances-vejiga-2025",
      "title": "Avances clínicos: seom-avances-vejiga-2025",
      "url": "https://www.seom.org/images/Avances_Cancer_de_Vejiga_2025.pdf",
      "r2_key": "evidence/v5/seom-avances-vejiga-2025.pdf",
      "sha256": "56b84698d0caef52a839aa8e91ea73285fa3fe67dc23c28b746fcc545cb13f21",
      "published_at": "2025",
      "consulted_at": "2026-11-06",
      "mime_type": "application/pdf",
      "retention_note": "22.435 casos 2025, 3.570 muertes hombres; sin costes o prevalencia. Indicencia y periodo; no parámetro monetario"
    },
    {
      "id": "doc-seom-cifras-2026",
      "source_id": "seom-cifras-2026",
      "title": "Epidemiología: seom-cifras-2026",
      "url": "https://www.seom.org/images/Las_Cifras_del_Cancer_en_Espanya_2026.pdf",
      "r2_key": "evidence/v5/seom-cifras-2026.pdf",
      "sha256": "25062895164fb0d9f83447e01dab6633b9c82f148d9c0567819f2469ff4aedf1",
      "published_at": "2026",
      "consulted_at": "2026-11-06",
      "mime_type": "application/pdf",
      "retention_note": "Tabla 2 p13: 23.929; fig9-12 p27–35: vejiga H 149.795/62.462 y M 32.692/14.134 total/5a. 2026 aparte; prevalencia general no puede multiplicar avanzados"
    },
    {
      "id": "doc-aecc-coste-2020",
      "source_id": "aecc-coste-2020",
      "title": "Coste enfermedad: aecc-coste-2020",
      "url": "https://www.contraelcancer.es/sites/default/files/content-file/Informe-Los-costes-cancer.pdf",
      "r2_key": "evidence/v5/aecc-coste-2020.pdf",
      "sha256": "c7d4b0fffd3f3473ad7745b089bf36fd56e82df4728911508784d94b2be1bdfc",
      "published_at": "2020",
      "consulted_at": "2026-11-06",
      "mime_type": "application/pdf",
      "retention_note": "Tabla 4 p13: vejiga local 11.820 €, metastásico 29.718 € (tratamiento 2018, no farmaco); tabla 6 farmacia+parafarmacia paciente. Contexto económico no farmacológico, no gasto observado farmacológico"
    },
    {
      "id": "doc-oncologicos-2016-2021",
      "source_id": "oncologicos-2016-2021",
      "title": "Consumo oncológico: oncologicos-2016-2021",
      "url": "https://www.sanidad.gob.es/areas/farmacia/publicaciones/informes/docs/20220402_Informe_Evol_SNS_Medicamentos_Oncologicos_L01L02_Def2.pdf",
      "r2_key": "evidence/v5/oncologicos-2016-2021.pdf",
      "sha256": "9e66581c8c7f1dcc1f36e7eb5631487946223d51e096ba187e6a8542d40dd574",
      "published_at": "2022, datos 2016–2021",
      "consulted_at": "2026-11-06",
      "mime_type": "application/pdf",
      "retention_note": "Tabla 9 p20: 3.109.920.000 € total, 2.898.200.000 hospital; PVL−RDL; tabla 10 evolución. Oncológico total, no vejiga"
    },
    {
      "id": "doc-eco-observatorio-2017",
      "source_id": "eco-observatorio-2017",
      "title": "Acceso innovación: eco-observatorio-2017",
      "url": "https://gepac.es/cuestionestado/pdf/Informe%20Observatorio%20Eco.pdf",
      "r2_key": "evidence/v5/eco-observatorio-2017.pdf",
      "sha256": "d087d576e505a56465f57457d1de75c6d95acc0f06a133b7c4f75f2b500ff597",
      "published_at": "2017",
      "consulted_at": "2026-11-06",
      "mime_type": "application/pdf",
      "retention_note": "indicadores gasto salud, acceso, demoras; no gasto farmacológico vejiga. Contexto; sin cifra utilizable C67"
    },
    {
      "id": "doc-estrategia-2021",
      "source_id": "estrategia-2021",
      "title": "Estrategia: estrategia-2021",
      "url": "https://www.sanidad.gob.es/areas/calidadAsistencial/estrategias/cancer/docs/ESTRATEGIA_EN_CANCER_DEL_SNS.pdf",
      "r2_key": "evidence/v5/estrategia-2021.pdf",
      "sha256": "e846b8b6fb80ab71c8cb8b578c3e5d77273692d768d989143c8b282c73b59532",
      "published_at": "2021",
      "consulted_at": "2026-11-06",
      "mime_type": "application/pdf",
      "retention_note": "275 páginas; marco de datos/equidad, no coste farmaco vejiga ni oncológico. Organización/custodia, no cifra"
    },
    {
      "id": "doc-seom-avelumab-2021",
      "source_id": "seom-avelumab-2021",
      "title": "Evaluación fármaco: seom-avelumab-2021",
      "url": "https://www.seom.org/informes-evaluacion-farmacos/IEV_SEOM_Avelumab_carcinoma_urotelial_avanzado.pdf",
      "r2_key": "evidence/v5/seom-avelumab-2021.pdf",
      "sha256": "fe070a117643adc413bd990e05dbd5cb0673ee3ad48469f5eff732f30718c517",
      "published_at": "2021",
      "consulted_at": "2026-11-06",
      "mime_type": "application/pdf",
      "retention_note": "p1:90% urotelial vejiga; p2 máximo 6 ciclos 1L; p7–8 revisión farmacoeconómica, sin gasto SNS. Clínico/contexto 90% no aplicado a 2025 vía superiores"
    },
    {
      "id": "doc-sefh-genitourinario-2026",
      "source_id": "sefh-genitourinario-2026",
      "title": "Monografía clínica: sefh-genitourinario-2026",
      "url": "https://gruposdetrabajo.sefh.es/gedefo/images/2026/monografiaGENITOURINARIO_2026.pdf",
      "r2_key": "evidence/v5/sefh-genitourinario-2026.pdf",
      "sha256": "03c687bc2701663702a44e9f93977fe24480ca35e04b533341770c4d1ac53088",
      "published_at": "2026",
      "consulted_at": "2026-11-06",
      "mime_type": "application/pdf",
      "retention_note": "Tratamientos y ensayos; no gasto observado vejiga. 2026 separado, contexto clínico"
    },
    {
      "id": "doc-iqvia-im-2025",
      "source_id": "iqvia-im-2025",
      "title": "Total mercado oncológico enero–diciembre 2025",
      "url": "https://www.immedicohospitalario.es/revista/80/12/",
      "r2_key": null,
      "sha256": null,
      "published_at": "2026, datos 2025",
      "consulted_at": "2026-11-06",
      "mime_type": "text/html",
      "retention_note": "Página 12 tabla IQVIA EMH; valores no están incluidos descuentos ni techos de gasto"
    }
  ],
  "meta": {
    "table": "source_documents",
    "count": 24,
    "limit": 100,
    "model_version": "v5-2026-11-06",
    "scope_note": "Observado general SNS no equivale a atribución vejiga; consultar source_documents vinculados."
  }
}